Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency - PubMed (original) (raw)
doi: 10.1038/gt.2013.19. Epub 2013 May 2.
Y Ma, J Li, H-S Shi, L-Q Wang, F-C Guo, J Zhang, D Li, B-H Mo, F Wen, T Liu, Y-T Liu, Y-S Wang, Y-Q Wei
Affiliations
- PMID: 23636245
- DOI: 10.1038/gt.2013.19
Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency
W Wang et al. Gene Ther. 2013 Oct.
Abstract
Immunotherapy that is based on adoptive transfer of T lymphocytes, which are genetically modified to express chimeric antigen receptors (CARs) that recognize tumor-associated antigens, has been demonstrated to be an efficient cancer therapy. Vascular endothelial growth factor receptor-1 (VEGFR-1), a vital molecule involved in tumor growth and angiogenesis, has not been targeted by CAR-modified T lymphocytes. In this study, we generated CAR-modified T lymphocytes with human VEGFR-1 specificity (V-1 CAR) by electroporation. V-1 CAR-modified T lymphocytes were demonstrated to elicit lytic cytotoxicity to target cells in a VEGFR-1-dependent manner. The adoptive transfer of V-1 CAR T lymphocytes delayed tumor growth and formation and inhibited pulmonary metastasis in xenograft models and such efficacies were enhanced by cotransfer of T lymphocytes that expressed interleukin-15 (IL-15). Moreover, V-1 CAR-modified T lymphocytes lysed primary endothelial cells and impaired tube formation, in vitro. These data demonstrated the antitumor and anti-angiogenesis ability of V-1 CAR-modified T lymphocytes. Our study provides the rationale for the clinical translation of CAR-modified T lymphocytes with VEGFR-1 specificity.
Similar articles
- Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q, Gomes EM, Lo AS, Junghans RP. Ma Q, et al. Prostate. 2014 Feb;74(3):286-96. doi: 10.1002/pros.22749. Prostate. 2014. PMID: 24174378 - Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K, Yanagihara K, Takigahira M, Kitanaka A, Imai C, Bhattacharyya J, Kubo T, Takei Y, Yasunaga S, Takihara Y, Kimura A. Mihara K, et al. Br J Haematol. 2010 Oct;151(1):37-46. doi: 10.1111/j.1365-2141.2010.08297.x. Epub 2010 Jul 30. Br J Haematol. 2010. PMID: 20678160 - Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z, Wu Y, Ma W, Zhang S, Zhang YQ. Deng Z, et al. BMC Immunol. 2015 Jan 31;16(1):1. doi: 10.1186/s12865-014-0064-x. BMC Immunol. 2015. PMID: 25636521 Free PMC article. - Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Shirasu N, Kuroki M. Shirasu N, et al. Anticancer Res. 2012 Jun;32(6):2377-83. Anticancer Res. 2012. PMID: 22641678 Review. - Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
Liu L, Sun M, Wang Z. Liu L, et al. Cancer Lett. 2012 Mar;316(1):1-5. doi: 10.1016/j.canlet.2011.10.027. Epub 2011 Oct 29. Cancer Lett. 2012. PMID: 22099879 Review.
Cited by
- Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy.
Kashyap D, Salman H. Kashyap D, et al. Int J Mol Sci. 2024 Mar 28;25(7):3780. doi: 10.3390/ijms25073780. Int J Mol Sci. 2024. PMID: 38612592 Free PMC article. Review. - Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets.
Pessino G, Scotti C, Maggi M, Immuno-Hub Consortium. Pessino G, et al. Cancers (Basel). 2024 Feb 23;16(5):901. doi: 10.3390/cancers16050901. Cancers (Basel). 2024. PMID: 38473265 Free PMC article. Review. - Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).
Yu T, Jiang W, Wang Y, Zhou Y, Jiao J, Wu M. Yu T, et al. Int J Oncol. 2024 Apr;64(4):40. doi: 10.3892/ijo.2024.5628. Epub 2024 Feb 23. Int J Oncol. 2024. PMID: 38390935 Free PMC article. Review. - Clinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy.
Meo C, de Nigris F. Meo C, et al. Cancers (Basel). 2024 Jan 23;16(3):491. doi: 10.3390/cancers16030491. Cancers (Basel). 2024. PMID: 38339244 Free PMC article. Review. - Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin.
Zhang Z, Liu C, Wang M, Sun R, Yang Z, Hua Z, Wu Y, Wu M, Wang H, Qiu W, Yin H, Yang M. Zhang Z, et al. J Immunother Cancer. 2023 Aug;11(8):e007199. doi: 10.1136/jitc-2023-007199. J Immunother Cancer. 2023. PMID: 37586774 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources